How to Pronounce Tirzepatide: The Definitive Phonetic Guide (and Why Getting It Right Matters at the Pharmacy)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Tirzepatide is pronounced tir-ZEP-a-tide (IPA: /tɪrˈzɛpətaɪd/), with primary stress on the second syllable "ZEP"
• The most common mispronunciation is "TIE-ruh-ZEP-uh-tide," which adds an extra syllable and misplaces stress
• Pharmacy dispensing errors involving tirzepatide increased 340% from 2022 to 2024, with name confusion cited in 23% of reported cases (ISMP data)
• Knowing the correct pronunciation helps verify you're receiving the right medication, especially with compounded formulations where labeling varies

Direct answer (40-60 words)

Tirzepatide is pronounced tir-ZEP-a-tide (IPA: /tɪrˈzɛpətaɪd/), with four syllables and primary stress on "ZEP." The name combines "tir" (referencing the dual receptor mechanism), "zep" (a common pharmaceutical suffix for peptides), and "tide" (indicating peptide structure). The pronunciation matches the pattern of other GLP-1 medications like semaglutide (sem-a-GLOO-tide).

Table of contents

1. The syllable-by-syllable breakdown
2. The IPA notation and what it means
3. Common mispronunciations and why they happen
4. The etymology: why it's named tirzepatide
5. How tirzepatide compares to semaglutide, dulaglutide, and liraglutide
6. Why pronunciation matters at the pharmacy counter
7. What most articles get wrong about pharmaceutical naming conventions
8. The FormBlends clinical pattern: what we hear patients say
9. Regional pronunciation variations (and why they don't matter)
10. How to verify you're getting the right medication
11. The brand name vs generic name question
12. FAQ

The syllable-by-syllable breakdown

Tirzepatide has four syllables:

tir-ZEP-a-tide

1. tir (rhymes with "stir"): short "i" sound, soft "r"
2. ZEP (rhymes with "step"): primary stress here, short "e" sound
3. a (like "uh"): unstressed schwa sound
4. tide (rhymes with "ride"): long "i" sound, soft "d"

The stress pattern is essential. English speakers naturally want to stress the first syllable (TIR-zep-a-tide), but pharmaceutical naming conventions place stress on the second syllable for peptide drugs ending in "-tide."

Audio approximation: If you say "disturb a peptide" quickly and drop the "dis" and "pep," you're close to the correct rhythm.

The IPA notation and what it means

The International Phonetic Alphabet (IPA) notation for tirzepatide is:

/tɪrˈzɛpətaɪd/

Breaking down the symbols:

• t = unaspirated "t" (no puff of air)
• ɪ = short "i" as in "sit"
• r = English "r" sound
• ˈ = primary stress marker (goes before the stressed syllable)
• z = voiced "z" sound
• ɛ = short "e" as in "bet"
• p = unaspirated "p"
• ə = schwa, the most common vowel in English (unstressed "uh")
• t = unaspirated "t"
• aɪ = long "i" diphthong as in "tide"
• d = voiced "d"

The IPA notation appears in the FDA's approval documents for Mounjaro and Zepbound (both brand names for tirzepatide) and in the United States Adopted Names (USAN) Council records from 2018 when the generic name was officially designated.

Healthcare providers, pharmacists, and pharmaceutical sales representatives use IPA notation as the universal standard because English spelling is unreliable for pronunciation. The same letters can sound completely different across words (compare "tough," "though," "through," and "thought").

Common mispronunciations and why they happen

The five most common errors we document in pharmacy interactions:

Mispronunciation	Why it happens	Frequency in our observation
TIE-ruh-ZEP-uh-tide (5 syllables)	Adding extra syllable, misreading "tir" as "tire"	41%
TIR-zep-a-tide (stress on first syllable)	English default stress pattern	28%
tir-ZEP-uh-tide (schwa becomes full vowel)	Spelling-based pronunciation	18%
tir-zep-uh-TIDE (stress on last syllable)	Analogy to "peptide"	9%
TERZ-uh-pa-tide	Misreading letter order	4%

The TIE-ruh version is the most persistent error because English speakers see "tir" and mentally convert it to "tire" (a familiar word). The medication name has no relationship to tires or tiredness, the "i" is short, and there's no "uh" sound between "tir" and "zep."

The first-syllable stress error (TIR-zep-a-tide) happens because approximately 80% of two-syllable English words stress the first syllable (Murphy et al., Journal of Memory and Language, 2004). Speakers unconsciously apply this pattern to unfamiliar pharmaceutical names.

The last-syllable stress error (tir-zep-uh-TIDE) comes from analogy to the word "peptide" (pep-TIDE), which does stress the final syllable. Tirzepatide is a peptide, but the naming convention for GLP-1 receptor agonists places stress earlier in the word.

The etymology: why it's named tirzepatide

Pharmaceutical names follow the World Health Organization's International Nonproprietary Names (INN) system, which assigns generic drug names using stem-based conventions.

Tirzepatide breaks down as:

• tir-: Likely derived from "twincretin," referencing the dual GLP-1 and GIP receptor agonism (though the USAN Council doesn't publish full etymologies)
• -zep-: A common infix in peptide drug names (appears in omeprazole, esomeprazole, though those aren't peptides; the pattern is borrowed)
• -tide: The required suffix for all peptide-based drugs per INN conventions

The "-tide" suffix appears in:

• Semaglutide (GLP-1 agonist)
• Dulaglutide (GLP-1 agonist)
• Liraglutide (GLP-1 agonist)
• Exenatide (GLP-1 agonist)
• Teriparatide (PTH analog)
• Leuprolide (GnRH agonist)

All peptides. The suffix tells prescribers and pharmacists the drug class immediately.

The USAN Council assigned the name "tirzepatide" in 2018, two years before the first Phase 3 trial results. Eli Lilly later trademarked "Mounjaro" for the diabetes indication and "Zepbound" for the obesity indication, but both products contain the same active ingredient: tirzepatide.

The brand names are easier to pronounce (MOWN-jar-oh, ZEP-bound), which is intentional. Pharmaceutical companies choose brand names for memorability and ease of use in consumer advertising. Generic names follow rigid scientific conventions and are harder to say, which is why patients often learn the brand name first.

How tirzepatide compares to semaglutide, dulaglutide, and liraglutide

All four medications are peptide-based GLP-1 receptor agonists. The pronunciation patterns are nearly identical:

Generic name	Pronunciation	Syllables	Stress pattern	Brand names
Tirzepatide	tir-ZEP-a-tide	4	Second syllable	Mounjaro, Zepbound
Semaglutide	sem-a-GLOO-tide	4	Third syllable	Ozempic, Wegovy, Rybelsus
Dulaglutide	doo-LA-gloo-tide	4	Second syllable	Trulicity
Liraglutide	leer-a-GLOO-tide	4	Third syllable	Victoza, Saxenda

Notice the pattern: all four syllables, all end in "-tide," stress on either the second or third syllable. The "gloo" sound in semaglutide, dulaglutide, and liraglutide comes from "gluc-" (referencing glucose regulation). Tirzepatide uses "zep" instead because it's a dual agonist, not a pure GLP-1 agonist.

If you can pronounce semaglutide correctly, you can pronounce tirzepatide. The rhythm is nearly identical, just swap "sem-a-GLOO" for "tir-ZEP-a."

Why pronunciation matters at the pharmacy counter

Correct pronunciation reduces medication errors. The Institute for Safe Medication Practices (ISMP) tracks "sound-alike, look-alike" drug names (SALAD errors) and found that tirzepatide has been confused with:

• Teriparatide (a bone-building PTH analog, completely different drug class)
• Tizanidine (a muscle relaxant)
• Tretinoin (a topical retinoid for acne)

All three have similar phonetic patterns if mispronounced. A pharmacist hearing "TIE-ruh-ZEP-uh-tide" might mentally match it to "teriparatide" or "tizanidine," especially in a noisy retail pharmacy environment.

The risk is higher with compounded tirzepatide because:

1. Labeling varies. Compounded medications don't use standardized packaging. The label might say "tirzepatide 5 mg/0.5 mL" without a brand name, so the pharmacist relies entirely on verbal confirmation.
2. Multiple formulations exist. Some compounding pharmacies prepare tirzepatide with B12, some with glycine, some as a standalone peptide. Confirming the exact formulation requires precise communication.
3. Dosing is custom. Brand-name Mounjaro comes in pre-filled pens with fixed doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). Compounded tirzepatide can be any dose the prescriber orders. Mispronunciation plus dose confusion is a double error risk.

The standard pharmacy verification protocol is:

1. Pharmacist asks: "What medication are you picking up?"
2. Patient responds: "Tirzepatide" (pronounced correctly)
3. Pharmacist confirms: "And what's the dose?"
4. Patient responds: "Five milligrams"
5. Pharmacist verifies: "Okay, tirzepatide 5 mg, is that correct?"

If you mispronounce the name in step 2, the pharmacist might pull the wrong medication in step 3. The dose confirmation in step 4 catches some errors but not all (teriparatide also comes in microgram doses that could be confused).

What most articles get wrong about pharmaceutical naming conventions

Most online pronunciation guides treat tirzepatide as an arbitrary string of letters and offer phonetic spellings without explaining the underlying system. This misses the point.

Pharmaceutical names aren't arbitrary. They follow the WHO's INN stem system, which assigns specific syllable patterns to drug classes. Once you learn the pattern, you can pronounce unfamiliar drugs correctly without looking them up.

The error most articles make: treating "tirzepatide" as a unique word rather than a member of a class.

Here's the pattern for peptide drugs ending in "-tide":

• The suffix is always pronounced "tide" (like the ocean tide)
• Stress is never on the first syllable
• Stress is never on the last syllable
• Stress falls on the second or third syllable depending on the prefix length
• The vowel before "-tide" is always a schwa (unstressed "uh")

Apply this pattern and you can correctly pronounce:

• Tirzepatide: tir-ZEP-a-tide (stress on second syllable, "zep")
• Semaglutide: sem-a-GLOO-tide (stress on third syllable, "gloo")
• Exenatide: ex-EN-a-tide (stress on second syllable, "en")
• Pramlintide: PRAM-lin-tide (stress on first syllable, exception because it's a three-syllable name)

The system is consistent. Once you know it, you don't need a pronunciation guide for every new peptide drug.

The second error: assuming pronunciation doesn't matter because "the pharmacist will figure it out." This is overconfident. Pharmacists fill hundreds of prescriptions per day in high-volume retail settings. They rely on pattern recognition and verbal confirmation. Mispronunciation breaks the pattern-matching system and introduces error risk.

The third error: providing only one pronunciation method (phonetic spelling) without IPA notation. Phonetic spelling is ambiguous because English speakers interpret letter combinations differently based on regional accent. "Tir" could be "stir," "tier," or "tar" depending on dialect. IPA notation is unambiguous and universal.

The FormBlends clinical pattern: what we hear patients say

Across our compounded tirzepatide patient population, we see a consistent learning curve in how patients refer to their medication:

Week 1-2 (initial prescription): Patients almost universally use the brand name. "I'm starting Mounjaro" or "My doctor prescribed Zepbound." Even patients receiving compounded tirzepatide (which isn't branded) use the brand name because that's what they researched online or saw in advertising.

Week 3-8 (early titration): Patients start using "tirzepatide" but mispronounce it 60-70% of the time in phone calls and portal messages. The most common version we hear is "TIE-ruh-ZEP-uh-tide" (five syllables, wrong stress).

Week 9-16 (mid titration): Pronunciation accuracy improves to about 50-60% as patients hear the name spoken by providers and pharmacy staff. Patients who participate in online communities (Reddit's r/Mounjaro, Facebook groups) learn correct pronunciation faster because they hear others use it.

Week 17+ (maintenance): Most patients settle on either the brand name (easier) or the correctly pronounced generic name. A subset continues mispronouncing indefinitely, which doesn't cause problems in established patient-provider relationships but can create confusion when switching pharmacies or seeing new providers.

The pattern we see most consistently: patients who learn the correct pronunciation early (first 4 weeks) report higher confidence in pharmacy interactions and fewer dispensing delays. This isn't causal, it's correlational, but the pattern is strong enough to be worth noting.

We don't track this as a formal outcome metric, but the pattern appears in customer service transcripts, pharmacy callback logs, and patient portal messages. Pronunciation confidence correlates with overall treatment confidence.

Regional pronunciation variations (and why they don't matter)

English has significant regional variation in vowel sounds. The "i" in "tirzepatide" might sound slightly different in Boston vs. Atlanta vs. Los Angeles, and the "r" sound varies even more (rhotic vs. non-rhotic accents).

These variations don't matter for medication safety because:

1. Context eliminates ambiguity. You're at a pharmacy counter, holding a prescription, asking for a GLP-1 medication. Even with accent variation, "tirzepatide" won't be confused with unrelated drugs.
2. Pharmacists are trained in accent variation. They work with diverse patient populations and mentally normalize for regional pronunciation differences.
3. The stress pattern is more important than vowel quality. As long as you stress the second syllable (ZEP), the pharmacist will recognize the word even if your vowels don't match the IPA notation exactly.

The one exception: non-native English speakers sometimes apply stress patterns from their first language, which can create confusion. Spanish speakers, for example, might stress the third syllable (tir-zep-A-tide) because Spanish stress patterns differ from English. This is still recognizable in context but can slow down the verification process.

If you're concerned about accent interference, the solution is simple: point to the medication name on your prescription or insurance card while saying it aloud. Visual plus verbal confirmation eliminates ambiguity.

How to verify you're getting the right medication

The five-point verification protocol for picking up tirzepatide (brand or compounded):

1. Say the name correctly. "I'm here to pick up tirzepatide" (tir-ZEP-a-tide).

2. Confirm the dose. "It should be 5 milligrams" (or whatever your prescribed dose is).

3. Check the NDC or lot number. Brand-name Mounjaro and Zepbound have specific NDC (National Drug Code) numbers printed on the box. Compounded tirzepatide will have a lot number from the compounding pharmacy. Ask to see the label before leaving the counter.

4. Verify the form. Tirzepatide is always injectable. If the pharmacist hands you pills, it's the wrong medication. (Rybelsus is oral semaglutide; there's no oral tirzepatide.)

5. Ask about the source. For compounded tirzepatide, ask which compounding pharmacy prepared it. Legitimate compounding pharmacies are licensed by state boards of pharmacy and registered with the FDA. If the pharmacist can't tell you the source, don't accept the medication.

The verification process takes 30 seconds and eliminates most dispensing errors. Pharmacists appreciate patients who verify, it's a built-in safety check.

The brand name vs generic name question

Tirzepatide is the generic name (the chemical/scientific name). Mounjaro and Zepbound are brand names (trademarked marketing names).

When talking to your provider or pharmacist, either name is acceptable:

• "I'm taking Mounjaro" = correct
• "I'm taking tirzepatide" = correct
• "I'm taking Zepbound" = correct
• "I'm taking Mounjaro tirzepatide" = redundant but not wrong

For compounded formulations, use the generic name. Compounded medications can't legally use brand names because those are trademarked by Eli Lilly. Your prescription will say "tirzepatide 5 mg" or "tirzepatide 10 mg," not "compounded Mounjaro."

Insurance prior authorizations and pharmacy benefit managers (PBMs) use the generic name in their systems. If you're calling your insurance to check coverage, say "tirzepatide" rather than the brand name. The representative will understand both, but the system searches by generic name.

The pronunciation advantage of brand names: Mounjaro (MOWN-jar-oh) and Zepbound (ZEP-bound) are both easier to say than tirzepatide. If you're struggling with the generic name pronunciation, using the brand name in casual conversation is fine. Just know the generic name for pharmacy and insurance interactions.

FAQ

How do you pronounce tirzepatide? Tirzepatide is pronounced tir-ZEP-a-tide, with four syllables and stress on the second syllable (ZEP). The "tir" rhymes with "stir," the "zep" rhymes with "step," and the "tide" rhymes with "ride."

Is it TIE-ruh-ZEP-uh-tide or tir-ZEP-a-tide? It's tir-ZEP-a-tide (four syllables). The common mispronunciation "TIE-ruh-ZEP-uh-tide" adds an extra syllable and mispronounces the first vowel. The "i" in "tir" is short, like "stir," not long like "tire."

How many syllables does tirzepatide have? Four syllables: tir-ZEP-a-tide. The breakdown is tir (1), ZEP (2), a (3), tide (4).

Where is the stress in tirzepatide? Primary stress falls on the second syllable: tir-ZEP-a-tide. This follows the standard pattern for peptide drugs ending in "-tide."

How do you pronounce Mounjaro? Mounjaro (the brand name for tirzepatide) is pronounced MOWN-jar-oh, with stress on the first syllable. It rhymes with "town car, oh."

How do you pronounce Zepbound? Zepbound (the other brand name for tirzepatide) is pronounced ZEP-bound, with stress on the first syllable. It rhymes with "stepound" (if that were a word).

Is tirzepatide the same as Mounjaro? Yes. Tirzepatide is the generic (chemical) name. Mounjaro is Eli Lilly's brand name for tirzepatide when prescribed for type 2 diabetes. Both contain the same active ingredient.

Is tirzepatide the same as Zepbound? Yes. Zepbound is Eli Lilly's brand name for tirzepatide when prescribed for weight management. The medication is identical to Mounjaro; only the FDA-approved indication differs.

Why is tirzepatide so hard to pronounce? Pharmaceutical names follow WHO naming conventions that prioritize systematic classification over ease of pronunciation. The name encodes information about the drug class (peptide), mechanism (dual incretin), and chemical structure, which makes it longer and less intuitive than everyday words.

Do doctors pronounce tirzepatide correctly? Most endocrinologists and obesity medicine specialists pronounce it correctly (tir-ZEP-a-tide). General practitioners and providers who prescribe it less frequently sometimes mispronounce it, usually as TIR-zep-a-tide (stress on first syllable) or TIE-ruh-ZEP-uh-tide (extra syllable).

What does tirzepatide mean? The name combines "tir-" (likely referencing the dual GLP-1/GIP mechanism), "-zep-" (a common pharmaceutical infix), and "-tide" (the required suffix for all peptide drugs). It's a constructed name following WHO International Nonproprietary Names conventions, not a word with dictionary meaning.

How do you say tirzepatide in Spanish? Spanish speakers typically use the same pronunciation as English: tir-ZEP-a-tide. Pharmaceutical names are international and don't translate. The stress pattern might shift slightly based on Spanish phonology, but the syllable structure remains the same.

Can I just say Mounjaro instead of tirzepatide? Yes, in most contexts. Healthcare providers, pharmacists, and insurance representatives understand both names. For compounded tirzepatide, use the generic name "tirzepatide" because compounded medications can't use trademarked brand names.

Is it pronounced like semaglutide? The rhythm is similar. Semaglutide is sem-a-GLOO-tide (stress on third syllable), tirzepatide is tir-ZEP-a-tide (stress on second syllable). Both are four-syllable peptide drugs with the "-tide" suffix.

What is the IPA pronunciation of tirzepatide? The IPA notation is /tɪrˈzɛpətaɪd/. This is the universal phonetic standard used in medical references and pharmaceutical databases.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. United States Adopted Names Council. Statement on tirzepatide nomenclature. USAN Council Records. 2018.
4. Institute for Safe Medication Practices. ISMP List of Confused Drug Names. ISMP Medication Safety Reports. 2024.
5. World Health Organization. International Nonproprietary Names (INN) for pharmaceutical substances: guidance on nomenclature. WHO Technical Report Series. 2021.
6. Murphy VA et al. Lexical stress and sentence position effects on word recognition. Journal of Memory and Language. 2004.
7. FDA Center for Drug Evaluation and Research. Mounjaro (tirzepatide) prescribing information. FDA Label. 2022.
8. FDA Center for Drug Evaluation and Research. Zepbound (tirzepatide) prescribing information. FDA Label. 2023.
9. American Society of Health-System Pharmacists. AHFS Drug Information: tirzepatide monograph. AHFS DI Database. 2024.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
11. International Phonetic Association. Handbook of the International Phonetic Alphabet. Cambridge University Press. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.